Molecular Neuroimaging in Alzheimer's Disease

Neuroimaging Clinics of North America

Volumn 22, Issue 1, 2012, Pages 57-65

  Matsuda, Hiroshi ^a   Imabayashi, Etsuko ^a  

^a SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

Author keywords

Alzheimer's disease; Mild cognitive impairment; PET; PiB

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; FLUORODEOXYGLUCOSE; PITTSBURGH COMPOUND B;

ALZHEIMER DISEASE; APOLIPOPROTEIN E GENE; BRAIN SIZE; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; EPISODIC MEMORY; GENE; GENETIC RISK; HUMAN; IMAGE ANALYSIS; MILD COGNITIVE IMPAIRMENT; MOLECULAR IMAGING; NEUROIMAGING; NEUROPATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN METABOLISM; REVIEW; SENSITIVITY AND SPECIFICITY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; BRAIN; HUMANS; MOLECULAR IMAGING; NEUROIMAGING; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 84856241080     PISSN: 10525149     EISSN: 15579867     Source Type: Journal    
DOI: 10.1016/j.nic.2011.11.005     Document Type: Review

References (48)

1. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297(5580):353-356.
2. 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. JMed Chem 2003, 46(13):2740-2754.
3. Klunk W.E., Engler H., Nordberg A., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004, 55(3):306-319.
4. Bacskai B.J., Frosch M.P., Freeman S.H., et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol 2007, 64(3):431-434.
5. Ikonomovic M.D., Klunk W.E., Abrahamson E.E., et al. Post-mortem correlates of invivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008, 131(Pt 6):1630-1645.
6. 18F-FDG PET for detection of Alzheimer's disease. JNucl Med 2007, 48(4):547-552.
7. Fodero-Tavoletti M.T., Rowe C.C., McLean C.A., et al. Characterization of PiB binding to white matter in Alzheimer disease and other dementias. JNucl Med 2009, 50(2):198-204.
8. Logan J. Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl Med Biol 2000, 27(7):661-670.
9. 11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006, 67(3):446-452.
10. Koivunen J., Verkkoniemi A., Aalto S., et al. PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease. Brain 2008, 131(Pt 7):1845-1853.
11. Lopresti B.J., Klunk W.E., Mathis C.A., et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. JNucl Med 2005, 46(12):1959-1972.
12. McNamee R.L., Yee S.H., Price J.C., et al. Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements. JNucl Med 2009, 50(3):348-355.
13. 11C-PIB scans for diagnosing Alzheimer's disease. JNucl Med 2008, 49(8):1262-1269.
14. Villemagne V.L., Pike K.E., Chételat G., et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol 2011, 69(1):181-192.
15. Bennett D.A., Schneider J.A., Arvanitakis Z., et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 2006, 66(12):1837-1844.
16. Hulette C.M., Welsh-Bohmer K.A., Murray M.G., et al. Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol 1998, 57(12):1168-1174.
17. Pike K.E., Savage G., Villemagne V.L., et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007, 130(Pt 11):2837-2844.
18. Jack C.R., Lowe V.J., Senjem M.L., et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008, 131(Pt 3):665-680.
19. Aizenstein H.J., Nebes R.D., Saxton J.A., et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008, 65(11):1509-1517.
20. Mormino E.C., Kluth J.T., Madison C.M., et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009, 132(Pt 5):1310-1323.
21. Braak H., Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997, 18(4):351-357.
22. Rowe C.C., Ellis K.A., Rimajova M., et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010, 31(8):1275-1283.
23. Mosconi L., Rinne J.O., Tsui W.H., et al. Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's. Proc Natl Acad Sci U S A 2010, 107(13):5949-5954.
24. Reiman E.M., Chen K., Liu X., et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 2009, 106(16):6820-6825.
25. Langbaum J.B., Chen K., Launer L.J., et al. Blood pressure is associated with higher brain amyloid burden and lower glucose metabolism in healthy late middle-age persons. Neurobiol Aging 2011, [Epub ahead of print].
26. Li N.C., Lee A., Whitmer R.A., et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010, 340:b5465.
27. Rowe C.C., Ng S., Ackermann U., et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007, 68(20):1718-1725.
28. Becker J.A., Hedden T., Carmasin J., et al. Amyloid-β associated cortical thinning in clinically normal elderly. Ann Neurol 2011, 69(6):1032-1042.
29. Oh H., Mormino E.C., Madison C., et al. β-Amyloid affects frontal and posterior brain networks in normal aging. Neuroimage 2011, 54(3):1887-1895.
30. Mormino E.C., Smiljic A., Hayenga A.O., et al. Relationships between beta-amyloid and functional connectivity in different components of the default mode network in aging. Cereb Cortex 2011, 21(10):2399-2407.
31. 11C-PiB and longitudinal brain atrophy in non-demented older individuals. Neurobiol Aging 2011, 32(12):2123-2130.
32. Jack C.R., Lowe V.J., Weigand S.D., et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009, 132(Pt 5):1355-1365.
33. Sojkova J., Zhou Y., An Y., et al. Longitudinal patterns of β-amyloid deposition in nondemented older adults. Arch Neurol 2011, 68(5):644-649.
34. Morris J.C., Roe C.M., Grant E.A., et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 2009, 66(12):1469-1475.
35. St George-Hyslop P.H., Morris J.C. Will anti-amyloid therapies work for Alzheimer's disease?. Lancet 2008, 372(9634):180-182.
36. Kemppainen N.M., Aalto S., Wilson I.A., et al. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 2007, 68(19):1603-1606.
37. Forsberg A., Engler H., Almkvist O., et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008, 29(10):1456-1465.
38. Wolk D.A., Price J.C., Saxton J.A., et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 2009, 65(5):557-568.
39. 18F]FDG PET study. Neurology 2007, 68(7):501-508.
40. Berg L., McKeel D.W., Miller J.P., et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 1998, 55(3):326-335.
41. Leinonen V., Alafuzoff I., Aalto S., et al. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol 2008, 65(10):1304-1309.
42. Cairns N.J., Ikonomovic M.D., Benzinger T., et al. Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol 2009, 66(12):1557-1562.
43. Fagan A.M., Mintun M.A., Mach R.H., et al. Inverse relation between invivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006, 59(3):512-519.
44. Fagan A.M., Head D., Shah A.R., et al. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol 2009, 65(2):176-183.
45. Klunk W.E., Price J.C., Mathis C.A., et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. JNeurosci 2007, 27(23):6174-6684.
46. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 2007, 68(15):1205-1212.
47. Fleisher A.S., Chen K., Liu X., et al. Using positron emission tomography and Florbetapir F 18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol 2011, 68(11):1404-1411.
48. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010, 9(4):363-372.